The hepatitis B epidemic and the urgent need for cure preparedness

Lazarus, Jeffrey V.; Block, Timothy M.; Bréchot, Christian; Kramvis, Anna; Miller, Veronica; Ninburg, Michael; Pénicaud, Capucine; Protzer, Ulrike; Razavi, Homie; Thomas, Laura; Wallace, Jack; Cowie, Benjamin C

doi:10.1038/s41575-018-0041-6

Cited by 24 publications

(14 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The targets of entecavir and potential targets of YZHG involved in the treatment of hepatitis B were docked, and the obtained affinity data were used as the baseline data of the positive control. The results showed that of the 18 groups of molecular docking data, only one group (entecavir positive control data) yielded higher values than the YZHG group 3 . This result suggests that their combination might play an important role in the treatment of hepatitis B with YZHG.…”

Section: Go and Kegg Enrichment Analysismentioning

confidence: 98%

A bioinformatics investigation into molecular mechanism of Yinzhihuang granules for treating hepatitis B by network pharmacology and molecular docking verification

Zhang

Liu

Zhou

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Yinzhihuang granules (YZHG) is a patented Chinese medicine for the treatment of hepatitis B. This study aimed to investigate the intrinsic mechanisms of YZHG in the treatment of hepatitis B and to provide new evidence and insights for its clinical application. The chemical compounds of YZHG were searched in the CNKI and PUBMED databases, and their putative targets were then predicted through a search of the SuperPred and Swiss Target Prediction databases. In addition, the targets of hepatitis B were obtained from TTD, PharmGKB and DisGeNET. The abovementioned data were visualized using Cytoscape 3.7.1, and network construction identified a total of 13 potential targets of YZHG in the treatment of hepatitis B. Molecular docking verification showed that CDK6, CDK2, TP53 and BRCA1 might be strongly correlated with hepatitis B treatment. Furthermore, GO and KEGG analyses indicated that the treatment of hepatitis B by YZHG might be related to positive regulation of transcription, positive regulation of gene expression, the hepatitis B pathway and the viral carcinogenesis pathway. Network pharmacology intuitively shows the multicomponent, multitarget and multichannel pharmacological effects of YZHG in the treatment of hepatitis B and provides a scientific basis for its mechanism of action. The cause of hepatitis B is hepatitis B virus (HBV), which is a double-stranded, circular, incompletely closed DNA virus 1-3. Antiviral therapy involving pegylated interferon or nucleoside analogs (lamivudine, adefovir, entecavir, tenofovir disoproxil, or tenofovir alafenamide) is currently provided clinically to patients with hepatitis B to inhibit HBV DNA replication and improve liver inflammation and fibrosis 4,5 , but this treatment protocol requires patients to be treated indefinitely and has a relatively low cure rate. Researchers are constantly searching for more effective drugs. In addition, the long-term use of nucleos(t)ide analogs (NAs) might lead to drug resistance and renal damage and cannot reverse liver fibrosis. Therefore, an increasing number of people have begun to focus on Chinese herbal medicines and seek safer and more cost-effective supplementary drugs for hepatitis B 6-8. Chinese herbal medicines have a long history of use in China. In recent years, researchers have continuously found effective pharmaceutical ingredients and targets for the treatment of diseases from Chinese herbal medicines. These results show that Chinese herbal medicines constitute extremely rich resources, and the discovery of new medicine sources from Chinese herbal medicine is becoming a major method of drug development. Yinzhihuang granules (YZHG) can clear away heat and toxic materials, promote diuresis and eliminate jaundice. The prescription is composed of "Yinchenhao Decoction" (Han, Zhongjing Zhang, "Treatise on Febrile Diseases") and "Huanglianjiedu Decoction" (Tang, Tao Wang, "Essential Secrets from Outside the Metropolis"). The YZHG

show abstract

Section: Go and Kegg Enrichment Analysismentioning

confidence: 98%

A bioinformatics investigation into molecular mechanism of Yinzhihuang granules for treating hepatitis B by network pharmacology and molecular docking verification

Zhang

Liu

Zhou

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Such efforts need to ensure up front that the resulting products are affordable to the communities that need access to them. The International Coalition to Eliminate Hepatitis B (ICE-HBV) ( 83 ) seeks to increase global awareness, facilitate collaboration for research discovery and support research in hepatitis B cure and mirrors the effective multisector campaign for HIV drug development. Modelling has demonstrated that availability of hepatitis B cure would accelerate achievement of global hepatitis B elimination(15).…”

Section: Hepatitis B Preventionmentioning

confidence: 99%

A global investment framework for the elimination of hepatitis B

Howell

Pedrana

Schroeder

et al. 2021

Journal of Hepatology

Self Cite

View full text Add to dashboard Cite

Background and Aims More than 292 million people are living with hepatitis B worldwide and are at risk of death from liver cirrhosis and liver cancer. The World Health Organization (WHO) has set global targets for the elimination of viral hepatitis as a public health threat by 2030. However, current levels of global investment in viral hepatitis elimination programmes are insufficient to achieve these goals. Methods To catalyse political commitment and to encourage domestic- and international-financing, we used published modelling data and key stakeholder interviews to develop an investment framework to demonstrate the return on investment for viral hepatitis elimination. Results The framework utilizes a public health approach to identify evidence-based national activities that reduce viral hepatitis-related morbidity and mortality, as well as international activities and critical enablers that allow countries to achieve maximum impact on health outcomes from investment to achieve WHO 2030 elimination targets. Conclusion Focusing on hepatitis B, this health policy paper employs the investment framework to estimate the substantial economic benefits of investing in the elimination of hepatitis B and demonstrates how such investments could be cost-saving by 2030.

show abstract

“…For HBV it is estimated that around two fifth of the world population has had an infection with this virus. Of these, 257 million were unable to clear the infection and are persistent virus carriers; around 880 000 individuals die every year from the consequence of HBV infection to a large part because the disease is widely under-diagnosed [8]. It is estimated that 15 -25 million HBV carriers are co-infected with HDV [4].…”

Section: Introductionmentioning

confidence: 99%

Towards curative therapy of chronic viral hepatitis

2019

Self Cite

View full text Add to dashboard Cite

Persistent infection with hepatitis viruses is a major medical burden that unfortunately is often ignored in the general public. This results in a massive under-diagnosis of these infections. According to the world health organization, the number of people dying every year from the consequence of hepatitis virus infection has surpassed the death rate caused by malaria and HIV and is equivalent to the one of tuberculosis. These numbers call for more intense efforts to devise more effective, ideally curative therapies that must become as widely accessible as they are e. g. for HIV infected individuals. A major step forward has been the development of curative antiviral therapy for chronic hepatitis C. In the case of hepatitis D virus, new drug candidates have been developed that should receive conditional approval very soon. For chronic hepatitis B, development is lagging behind but thanks to a re-emerging interest of pharmaceutical industry that was triggered by the success of hepatitis C therapy and the availability of novel infection systems, new attempts towards curative approaches for this highly prevalent infection are undertaken. Here we summarize the current status of therapy development for chronic viral hepatitis that ultimately aims at cure.

show abstract

The hepatitis B epidemic and the urgent need for cure preparedness

Cited by 24 publications

References 7 publications

A bioinformatics investigation into molecular mechanism of Yinzhihuang granules for treating hepatitis B by network pharmacology and molecular docking verification

A bioinformatics investigation into molecular mechanism of Yinzhihuang granules for treating hepatitis B by network pharmacology and molecular docking verification

A global investment framework for the elimination of hepatitis B

Towards curative therapy of chronic viral hepatitis

Contact Info

Product

Resources

About